Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 189

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 189
---
standing equity awards and warrants with respect to the number of shares of common stock subject to such award or warrant and the exercise price thereof. Furthermore, the number of shares of common stock available for issuance under the Company’s equity incentive plans were proportionately adjusted for the 2024 Reverse Split ratio, such that fewer shares are subject to such plans. All share numbers included herein have been retroactively adjusted to reflect the 1-for-30Reverse Split (see Note 8). Nasdaq Compliance As previously reported on October 16, 2024, the Company received a letter from Nasdaq Stock Market (“Nasdaq”) notifying the Company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) by failing to maintain a minimum bid price for its common stock of at least $ 1.00per share for 30consecutive business days. The Company had until February 14, 2025, to regain compliance by having a minimum closing bid price of at least $ 1.00per share for at least 10consecutive business days. On February 19, 2025 the Company received a formal notice from Nasdaq stating that the Company’s common stock will continue to be listed and traded on Nasdaq, due to the Company having regained compliance with the minimum bid price requirement, and all applicable listing standards. F-7 REVELATION BIOSCIENCES, INC.
Notes to the Consolidated Financial Statements 1. Organization and Basis of Presentation(cont.) Liquidity and Capital Resources Going Concern The Company has incurred recurring losses since its inception, including a net loss of $ 15.0million for the year ended December 31, 2024. As of December 31, 2024, the Company had an accumulated deficit of $ 40.5million, a stockholders’ equity of $ 4.7million and available cash and cash equivalents of $ 6.5million. The Company expects to continue to incur significant operating and net losses, as well as negative cash flows from operations, for the foreseeable future as it continues to complete all necessary product development or future commercialization efforts. The Company has never generated revenue and does not expect to generate revenue from product sales unless and until it successfully completes development and obtains regulatory approval for our Product Candidates or other product candidates, which the Company expects will not be for at least several years, if ever. The Company does not anticipate that its current cash and cash equivalents balance will be sufficient to sustain operations within one-year after the date that the Company